Friday, Mar 29 2024 | Time 19:39 Hrs(IST)
image
Press Releases » prnewswire


Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1%



MUMBAI, India, Sept. 21, 2021 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin®1 Foam, 1%, of Mylan Pharmaceuticals Inc.


Glenmark Logo

According to IQVIATM sales data for the 12 month period ending July 2021, the Evoclin® Foam, 1%, market2 achieved annual sales of approximately 12.0 million*.


Glenmark's current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


References:


1All brand names and trademarks are the property of their respective owners.


2Market includes brand and all available therapeutic equivalents


*IQVIATM National Sales Perspectives: Retail & Non-Retail, July 2021


About Glenmark Pharmaceuticals Ltd


Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It ranks among the world's top 50 Generics and Biosimilars companies (Top 50 Company Rankings, 2020, from Informa's Generics Bulletin). The company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world's most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index. For more information, visit www.glenmarkpharma.com 


Media Contact :

Udaykumar Murthy

Deputy General Manager

Corporate Communications

Glenmark Pharmaceuticals Ltd


Logo: http://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg



More News
A Customized Treatment Approach to Addiction Recovery Works Better, Abhasas Treatment Programs Includes Yoga, Meditation & Medications

A Customized Treatment Approach to Addiction Recovery Works Better, Abhasas Treatment Programs Includes Yoga, Meditation & Medications

29 Mar 2024 | 12:03 PM

A Customized Treatment Approach to Addiction Recovery Works Better, Abhasas Treatment Programs Includes Yoga, Meditation & Medications

see more..
Empowering breakthrough for former inmates by The Art of Living

Empowering breakthrough for former inmates by The Art of Living

29 Mar 2024 | 11:15 AM

Empowering breakthrough for former inmates by The Art of Living

see more..
IIIT Hyderabad signs MoU with Plaksha University to setup joint center for sustainability

IIIT Hyderabad signs MoU with Plaksha University to setup joint center for sustainability

29 Mar 2024 | 10:31 AM

IIIT Hyderabad signs MoU with Plaksha University to setup joint center for sustainability

see more..
Striking a Chord for Well-being: Swarnabhoomi Academy of Music Partners with Amaha for Mental Health

Striking a Chord for Well-being: Swarnabhoomi Academy of Music Partners with Amaha for Mental Health

28 Mar 2024 | 7:05 PM

Striking a Chord for Well-being: Swarnabhoomi Academy of Music Partners with Amaha for Mental Health

see more..
Azure Power Files Fiscal 2023 Annual Report on Form 20-F

Azure Power Files Fiscal 2023 Annual Report on Form 20-F

28 Mar 2024 | 6:31 PM

Azure Power Files Fiscal 2023 Annual Report on Form 20-F

see more..
image